Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02194491 · ClinicalTrials.gov registry record · Phase 1
A Positron Emission Tomography Occupancy Study Using Ligand [11C]AS2471907 and Following Oral Dosing of ASP3662
A Phase 1 study, sponsored by Astellas Pharma Global Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT02194491 is a Phase 1 study that has completed, run by Astellas Pharma Global Development. The registered enrollment target is 18 participants.
The verdict
NCT02194491, a Phase 1 study, has completed, sponsored by Astellas Pharma Global Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate a novel PET tracer (\[11C\]AS2471907), and to use \[11C\]AS2471907 to assess the level and time-course of enzyme occupancy in the human brain prior to and following single oral dose administration of ASP3662.
Interventions
- RADIATION Positron Emission Tomography (PET)
- OTHER [11C]AS2471907
- DRUG ASP3662
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2014-04 |
| Est. Completion | 2016-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02194491
The ClinicalTrials.gov registry entry for NCT02194491 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Global Development, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Positron Emission Tomography (PET) is the first listed.
NCT02194491 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02194491 about?
NCT02194491 is a clinical study titled "A Positron Emission Tomography Occupancy Study Using Ligand [11C]AS2471907 and Following Oral Dosing of ASP3662". The purpose of this study is to evaluate a novel PET tracer (\[11C\]AS2471907), and to use \[11C\]AS2471907 to assess the level and time-course of enzyme occupancy in the human brain prior to and following single oral dose administration of ASP3662.
What is the current status of trial NCT02194491?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2014-04. Estimated completion is 2016-05.
What interventions are being tested in trial NCT02194491?
The interventions under investigation include: Positron Emission Tomography (PET) (RADIATION), [11C]AS2471907 (OTHER), ASP3662 (DRUG).
Who is sponsoring clinical trial NCT02194491?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.